Nippon Kayaku and Solasia Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

On October 26, 2021 Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) and Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia")reported the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter "this agreement") (Press release, Nippon Kayaku, OCT 26, 2021, View Source [SID1234591936]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Darinaparsin is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma (PTCL). Solasia filed a new drug application with the Ministry of Health, Labour and Welfare in June 2021 and expects to launch after obtaining approval from the agency in 2022.

Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows: "Nippon Kayaku is one of Japan’s leading pharmaceutical companies with strengths in the field of oncology. We are very pleased to have this opportunity to deliver darinaparsin to nationwide medical institutions providing cancer treatment by utilizing Nippon Kayaku’s extensive experience in oncology and strong sales network, and contribute to the treatment of PTCL."

Mr. Kazuto Koizumi, Managing Director and Head of Pharmaceuticals Group of Nippon Kayaku, commented as follows: "Solasia is a specialty pharmaceutical company that excels in development of innovative medicines in the field of oncology in Japan and other Asian countries. Through the early launch of darinaparsin developed by Solasia, we expect to provide a new treatment option for PTCL, and contribute to patients and their family suffering from the disease, as well as to healthcare professionals."

Based on this agreement, Nippon Kayaku and Solasia will make further efforts to provide a new treatment option to patient suffering from PTCL, for which no standard treatment has been established to date.